{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-005595","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.799035+00:00","generated_at":"2026-06-06T20:46:19.577236+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TransCode raises $7.25M in public offering; expects to regain Nasdaq equity compliance","bullets":["Priced public offering of 5,942,623 shares (or pre-funded warrants) and warrants for 11,885,246 shares at $1.22/unit.","Gross proceeds of $7.25M; net proceeds for clinical trials of TTX-MC138 and working capital.","Offering closed Jan 22, 2024; warrants exercisable at $1.22, expire in 3.5 years.","Company believes stockholders' equity now above $2.5M; Nasdaq compliance plan submitted and under review.","H.C. Wainwright acted as placement agent; received agent warrants for 356,557 shares at $1.525."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-005595","json":"https://secwatch.observer/filing/0001104659-24-005595.json","markdown":"https://secwatch.observer/filing/0001104659-24-005595.md","text":"https://secwatch.observer/filing/0001104659-24-005595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465924005595/0001104659-24-005595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465924005595/tm243790d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:46:19.577236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf941a68a4e3e9102126c543b401617945f0e20f","claim":"Transcode Therapeutics, Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at approximately $7.25 million (effective 2024-01-18).","evidence_excerpt":"On January 18, 2024, TransCode Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465924005595/0001104659-24-005595-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers named therein"},{"label":"Value","value":"approximately $7.25 million"},{"label":"Effective","value":"2024-01-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}